Key points are not available for this paper at this time.
May support risk stratification with platelet markers in stable CAD; leaves open prospective validation before guiding care.
Department of Medicine, University of Vermont, Burlington, Vermont, USA Correspondence and requests for reprints to David J. Schneider MD, University of Vermont, 208 South Park Drive, Suite 2, Colchester, VT 05446, USA. Tel: + 1 802 656 8953; fax: + 1 802 656 8969; e-mail: [email protected]
No takes yet. Share an insight, caveat, or question.
David J. Schneider (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: